Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The aim of this study was to identify changes in the gene expression profile of Candida albicans upon exposure to the hydroxypyridone anti-infective agent ciclopirox olamine in an effort to better understand its mechanism of action. METHODS: C. albicans SC5314 was exposed to either medium alone or ciclopirox olamine at a concentration equivalent to the IC50 (0.24 mg/L) for 3 h. RNA was isolated and gene expression profiles were compared using DNA microarrays. Differential expression of select genes was confirmed by real-time reverse transcription (RT)-PCR. Mutants disrupted for CDR2 and both CDR1 and CDR2, as well as a clinical isolate overexpressing CDR1 and CDR2, were examined for changes in susceptibility to ciclopirox olamine. RESULTS: A total of 49 genes were found to be responsive to ciclopirox olamine, including 36 up-regulated genes and 13 down-regulated genes. These included genes involved in small molecule transport (HGT11, HXT5, ENA22, PHO84, CDR4), iron uptake (FRE30, FET34, FTR1, FTR2, SIT1) and cell stress (SOD1, SOD22, CDR1, DDR48). Mutants disrupted for CDR2 and both CDR1 and CDR2, as well as a clinical isolate overexpressing CDR1 and CDR2, showed no change in susceptibility to ciclopirox olamine compared with the respective parent. CONCLUSIONS: Consistent with the hypothesis that ciclopirox olamine acts as an iron chelator, it induced changes in expression of many genes involved in iron uptake. Despite induction of the multidrug efflux pump genes CDR1 and, to a lesser extent, CDR2 by ciclopirox olamine, these genes do not affect susceptibility to this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake.
Askwith, C., Eide, D., Van Ho, A., Bernard, P. S., Li, L., Davis-Kaplan, S., Sipe, D. M., & Kaplan, J. (1994) · Cell · doi:10.1016/0092-8674(94)90346-8 · Cited by 670
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Liu, T. T., Lee, R. E. B., Barker, K. S., Lee, R. E., Wei, L., Homayouni, R., & Rogers, P. D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2226-2236.2005 · Cited by 313
Self-citationHeymann, P., Gerads, M., Schaller, M., Dromer, F., Winkelmann, G., & Ernst, J. F. (2002) · Infection and Immunity · doi:10.1128/iai.70.9.5246-5255.2002 · Cited by 226 · cited 1×
“SIT1 is homologous to ScARN1, which encodes a putative siderophore transporter also believed to be involved in iron uptake.(31,32) Up-regulation of these genes suggests depletion of Table 1.”
BackgroundAgarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204 · cited 2×
“cerevisiae, for the purpose of examining the effects of antifungal agents on global gene expression.(23) Owing to the expense of these arrays, we were limited to a single concentration and single time-point.”
BackgroundMethodSelf-citationMolecular genetic analysis of azole antifungal mode of action
Kelly, S. L., Arnoldi, A., & Kelly, D. E. (1993) · Biochemical Society Transactions · doi:10.1042/bst0211034 · Cited by 106
Hu, C.-J., Bai, C., Zheng, X.-D., Wang, Y.-M., & Wang, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204545200 · Cited by 97 · cited 1×
“SIT1 is homologous to ScARN1, which encodes a putative siderophore transporter also believed to be involved in iron uptake.(31,32) Up-regulation of these genes suggests depletion of Table 1.”
Background
Research works printed but not linked: 26
- Beck-Sague, C. M. & Jarvis, W. R. (1993). Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System. Journal of Infectious Diseases167, 1247–51. · DOI · Paper page
- Pfaller, M. A., Jones, R. N., Messer, S. A. et al. (1998). National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagnostic Microbiology and Infectious Disease31, 327–32. · DOI · Paper page
- Gallis, H. A., Drew, R. H. & Pickard, W. W (1990). Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases12, 308–29. · DOI · Paper page
- Lyman, C. A. & Walsh, T. J. (1992). Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs44, 9–35. · DOI · Paper page
- Ghannoum, M. A. & Rice, L. B. (1999). Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews12, 501–17. · DOI · Paper page
- Sanglard, D. (2002). Resistance of human fungal pathogens to antifungal drugs. Current Opinion in Microbiology5, 379–85. · DOI · Paper page
- Groll, A. H. & Walsh, T. J. (2001). Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opinion on Investigational Drugs10, 1545–58. · DOI · Paper page
- Gupta, A. K. & Plott, T. (2004). Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. International Journal of Dermatology43, Suppl. 1, 3–8. · doi:10.1111/j.1461-1244.2004.02380.x
- Niewerth, M., Kunze, D., Seibold, M. et al. (2003). Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrobial Agents and Chemotherapy47, 1805–17. · DOI · Paper page
- Sakurai, K., Sakaguchi, T., Yamaguchi, H. et al. (1978). Studies on uptake of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296) by Candida albicans. Chemotherapy (Tokyo)24, 146–53. · doi:10.1159/000237774
- Sakurai, K., Sakaguchi, T., Yamaguchi, H. et al. (1978). Mode of action of 6-cyclohexyl-4-methyl-2(1H)-pyridone ethanolamine salt (HOE 296). Chemotherapy (Tokyo)24, 68–76. · DOI
- Abrams, B. B., Hänel, H. & Hoehler, T. (1992). Ciclopirox olamine: a hydroxypyridone antifungal agent. Clinical Dermatology9, 471–7. · DOI
- Jones, T., Federspiel, N. A., Chibana, H. et al. (2004). The diploid genome sequence of Candida albicans. Proceedings of the National Academy of Sciences, USA101, 7329–34. · DOI · Paper page
- Rogers, P. D. & Barker, K. S. (2002). Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrobial Agents and Chemotherapy46, 3412–7. · DOI · Paper page
- Rogers, P. D. & Barker, K. S. (2003). Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrobial Agents and Chemotherapy47, 220–7. · DOI · Paper page
- Barker, K. S., Crisp, S., Wiederhold, N. et al. (2004). Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy54, 376–85. · DOI · Paper page
- Schmitt, M. E., Brown, T. A. & Trumpower, B. L. (1990). A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Research18, 3091–2. · DOI · Paper page
- d'Enfert, C., Goyard, S., Rodriguez-Arnaveilhe, S. et al. (2005). CandidaDB: a genome database for Candida albicans pathogenomics. Nucleic Acids Research33, D353–7. · DOI · Paper page
- Kruckeberg, A. L. (1996). The hexose transporter family of Saccharomyces cerevisiae. Archives of Microbiology166, 283–92. · DOI · Paper page
- Wieland, J., Nitsche, A. M., Strayle, J. et al. (1995). The PMR2 gene cluster encodes functionally distinct isoforms of a putative Na+ pump in the yeast plasma membrane. EMBO Journal14, 3870–82. · DOI · Paper page
- Severance, S., Chakraborty, S. & Kosman, D. J. (2004). The Ftr1p iron permease in the yeast plasma membrane: orientation, topology and structure–function relationships. Biochemical Journal380, 487–96. · DOI · Paper page
- Georgatsou, E. & Alexandraki, D. (1999). Regulated expression of the Saccharomyces cerevisiae Fre1p/Fre2p Fe/Cu reductase related genes. Yeast15, 573–84. · DOI · Paper page
- Marvin, M. E., Williams, P. H. & Cashmore, A. M. (2003). The Candida albicans CTR1 gene encodes a functional copper transporter. Microbiology149, 1461–74. · DOI · Paper page
- Hwang, C. S., Rhie, G. E., Oh, J. H. et al. (2002). Copper- and zinc-containing superoxide dismutase (Cu/ZnSOD) is required for the protection of Candida albicans against oxidative stresses and the expression of its full virulence. Microbiology148, 3705–13. · DOI · Paper page
- Hwang, C. S., Baek, Y. U., Yim, H. S. et al. (2003). Protective roles of mitochondrial manganese-containing superoxide dismutase against various stresses in Candida albicans. Yeast20, 929–41. · DOI · Paper page
- Sanglard, D., Ischer, F., Monod, M. et al. (1997). Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology143, 405–16. · DOI · Paper page
Cited by
Candida albicans Cell Wall Proteins
Chaffin, W. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-07 · Cited by 515
“Expression decreased in response to treatment with caspofungin (transcriptional profiling [210]) and increased in response to ciclopirox olamine (transcriptional profiling [201).”
BackgroundAlmeida, R. S., Brunke, S., Albrecht, A., Thewes, S., Laue, M., Edwards, J. E., Filler, S. G., & Hube, B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000217 · Cited by 330
“albicans [81] and the anti Candida activity of ciclopiroxolamine, a potent antifungal agent, is proposed to be mediated by iron chelation [82–84].”
BackgroundGupta, A. K., Stec, N., Summerbell, R. C., Shear, N. H., Piguet, V., Tosti, A., & Piraccini, B. M. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16394 · Cited by 289
Sanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
Candida albicans iron acquisition within the host
Almeida, R. S., Wilson, D., & Hube, B. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00570.x · Cited by 199
“Finally, the anti-Candida activity of ciclopirox olamine, a potent antifungal agent, is proposed to be caused by iron chelation (Niewerth et al., 2003; Lee et al., 2005; Sigle et al., 2005).”
Background
Metadata
- Authors
- Lee, R. E. B., Liu, T. T., Barker, K. S., Lee, R. E., & Rogers, P. D.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-01
- Volume
- 55
- Issue
- 5
- Pages
- 655-662
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2155606031
- Cited by
- 58
- References
- 8
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.